Document is current
Any future updates will be listed below
-
Authors
Mounzer, Karam
Osterman, Michael D. https://orcid.org/0000-0003-4302-6596
Brunet, Laurence
Hsu, Ricky K.
Mills, Anthony M.
Pierone, Gerald Jr.
Sension, Michael G.
Fusco, Jennifer S.
Fleming, Sean P.
Prajapati, Girish
Fusco, Gregory P.
-
Funding
Funding for this research was provided by:
Merck Sharp & Dohme LLC
- License Information
-
More Information
Article History
Received: 5 February 2026
Accepted: 3 March 2026
First Online: 22 March 2026
Declarations
:
: Karam Mounzer has received research grants from Gilead Sciences, Merck, Janssen, and GSK/ViiV Healthcare and honoraria for Speakers Bureau and Advisory Boards from Gilead Sciences, Merck, Janssen and GSK/ViiV Healthcare; and advisory board participation with Epividian. Michael D. Osterman, Laurence Brunet, Jennifer S. Fusco, and Gregory P. Fusco are employed by Epividian, Inc.; Epividian has had research funded by AIDS Healthcare Foundation, EMD Serono, Gilead Sciences, Janssen Scientific Affairs, LLC, Merck & Co., Theratechnologies Inc., and ViiV Healthcare. Ricky K. Hsu has received research grants from Gilead Sciences and ViiV Healthcare, speaker honoraria from ViiV Healthcare, Merck and Gilead Sciences, and advisory board participation with ViiV Healthcare, Gilead Sciences, and Epividian. Anthony M. Mills has received research funding from Gilead, ViiV, GSK, Abbott, Roche, and Merck; he has attended advisory boards for Gilead, ViiV, and Epividian. Gerald Pierone, Jr. has received research funding paid to his institution from GSK/ViiV Healthcare, NIH/DAIDS, Gilead Sciences and Precision for Medicine, and is a member of the Epidemiology and Clinical Advisory Board for Epividian. Michael G. Sension is on the Speakers Bureau for ViiV Healthcare and Gilead Sciences, and on the advisory board for ViiV Healthcare and Epividian. Sean P. Fleming and Girish Prajapati are employed by Merck & Co., Inc. This work was supported by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
: Institutional review board (IRB) approval covering patient data contained in the OPERA database was received from Advarra IRB; a waiver of informed consent and authorization for the use of protected health information for patient data was granted (Pro00023648). The study was conducted in accordance with HIPAA and HITECH requirements, which expand upon the ethical principles detailed in the 1964 Declaration of Helsinki.
